Autosomal Dominant Intellectual Disability 32 (ADID-32)

Autosomal Dominant Intellectual Disability 32 (ADID-32) is a rare, genetic neurodevelopmental condition caused by changes (variants or “spelling mistakes”) in a gene called KAT6A on chromosome 8 (region 8p11.21). People with ADID-32 usually have global developmental delay, intellectual disability of variable degree, and late speech and language development. Many also have low muscle tone in infancy (hypotonia), feeding problems and reflux in early life, distinctive facial features (often a broad nasal tip and a thin, tented upper lip), and sometimes small head size (microcephaly). Congenital heart defects, gastrointestinal problems, sleep disturbance, squint/ptosis, and behavioral features (including autism traits) may also occur. Most variants arise de novo (new in the child), but the condition is autosomal dominant, so a person with the variant can pass it on. The disorder is also called KAT6A syndrome or Arboleda-Tham syndrome (ARTHS) and corresponds to MRD32/ADID-32 in older naming systems. Kat6A+3BioMed Central+3PMC+3

ADID-32 is a rare, autosomal-dominant neurodevelopmental disorder caused by pathogenic variants in KAT6A, a histone acetyltransferase that regulates how genes turn on and off during development. Children typically show global developmental delay, intellectual disability of variable degree, speech delay (often severe), hypotonia, feeding difficulty, and sometimes congenital heart, eye, gastrointestinal, or immune problems. Facial features can include a broad nasal tip and a thin, tented upper lip. The disorder has also been called Arboleda–Tham syndrome and autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects. PMC+2PMC+2

ADID-32 results from heterozygous loss-of-function or truncating variants in KAT6A (also known as MOZ/MYST3) on 8p11.21; most cases arise de novo, but the condition follows autosomal-dominant inheritance, so a parent with a pathogenic variant has a 50% chance to pass it to each child. KAT6A encodes a MYST-family histone acetyltransferase; disrupted chromatin remodeling is believed to underlie the multisystem phenotype. PMC+2Translational Pediatrics+2

Another names

This condition is known by several interchangeable names in the literature:

• KAT6A syndrome

• Arboleda-Tham syndrome (ARTHS)

• Autosomal dominant intellectual disability 32 (ADID-32)

• Mental retardation, autosomal dominant 32 (MRD32) (legacy term)
  All refer to pathogenic variants in the KAT6A gene. Kat6A+1

KAT6A makes a histone acetyltransferase protein that helps “open” DNA so other genes can be turned on at the right time during brain and body development. When KAT6A does not work correctly—because of truncating, splice-site, or certain missense variants—gene-expression programs are disrupted, especially those critical for early brain development, craniofacial formation, and heart/gut development. Many variants simply reduce the amount of functional KAT6A protein (haploinsufficiency). Some late-truncating variants in exons 16–17 may produce more severe clinical pictures, possibly via dominant-negative effects. MDPI+3Genetics of Speech+3PMC+3

Types

Clinically, ADID-32 is often grouped by variant class and location rather than by separate clinical “subtypes,” because the core features overlap:

1. Early truncating / loss-of-function variants (exons 1–15). Usually lead to a typical KAT6A syndrome profile via haploinsufficiency. Severity varies but can be milder than late truncating changes. Gimopen

2. Late truncating variants (exons 16–17). Frequently associated with more severe developmental delay, microcephaly, neonatal hypotonia, feeding and reflux problems, and more frequent cardiac defects in several series. UCLA Health+1

3. Splice-site variants. Can act like truncating variants; functional studies confirm pathogenic splicing in some cases. UQ eSpace

4. Missense variants (often at conserved residues). Less common; some series suggest particular amino-acid changes (e.g., serine residues) may present without cardiac involvement, but numbers are still small. BioMed Central

5. Inheritance pattern. Most are de novo, but familial transmission with variable expression is documented; the disorder is autosomal dominant, so each child of an affected parent has a 50% chance of inheriting the variant. BioMed Central

---

Causes

Because ADID-32 is a single-gene disorder, “causes” refer to the different ways KAT6A can be altered and the downstream effects. Each item below describes a distinct, evidence-based cause/mechanism or scenario that results in the same clinical condition:

1. Nonsense variants that introduce early stop signals, making a shortened, non-functional KAT6A protein. PMC

2. Frameshift variants (small insertions/deletions) that disrupt the reading frame, leading to premature stops. PMC

3. Canonical splice-site variants that mis-process RNA, often yielding truncated protein. UQ eSpace

4. Late-truncating variants in exons 16–17, frequently linked with more severe features. UCLA Health

5. Early-truncating variants in exons 1–15, typically causing haploinsufficiency with variable severity. Gimopen

6. Pathogenic missense variants that alter critical amino acids and impair KAT6A’s enzymatic/chromatin functions. BioMed Central

7. Exonic deletions within KAT6A (rare) that remove essential coding exons. (Mechanistically consistent with KAT6A loss-of-function in reported cohorts.) PMC

8. De novo events occurring at conception, explaining most cases. genetics.edu.au

9. Inherited autosomal dominant variants, leading to familial cases with variable features. ScienceDirect

10. Haploinsufficiency, where one normal copy isn’t enough to maintain normal gene regulation during development. Genetics of Speech

11. Dominant-negative effects from certain late truncations, where the abnormal protein interferes with the normal one. MDPI

12. Disruption of chromatin acetylation, reducing activation of target developmental genes. Wikipedia

13. Downstream neurodevelopmental pathway dysregulation, affecting neuronal maturation and connectivity. (Inferred from chromatin-modifier role and phenotypic spectrum.) PMC

14. Perturbed craniofacial gene programs, explaining consistent facial features. PMC

15. Cardiac developmental program disruption, contributing to septal defects/outflow anomalies in a subset. PMC

16. Oromotor/gastrointestinal neural control effects, linked with early feeding difficulties and reflux. genetics.pediatrics.med.ufl.edu

17. Sleep regulation effects, with reports of sleep disturbance in cohorts. BioMed Central

18. Visual system development involvement, underlying strabismus/ptosis in some patients. BioMed Central

19. Immune and endocrine associations (emerging)—rare reports suggest possible immune dysfunction or pituitary anomalies in some families (needs more data). ScienceDirect

20. Gene-regulatory network effects shared with other chromatin disorders, explaining overlaps with other “chromatinopathy” syndromes. MDPI

---

Symptoms

1. Developmental delay in sitting, crawling, walking, and self-help skills; milestones are achieved later than peers. PMC

2. Intellectual disability (mild to severe), with learning ability below age level and support needs at school and adulthood. BioMed Central

3. Speech and language delay, often the most striking feature; some children speak late or use few words and need intensive therapy. MDPI

4. Neonatal hypotonia (low muscle tone), making babies feel “floppy,” with delayed motor skills. PMC

5. Feeding difficulties and reflux in infancy; some need temporary tube feeding or anti-reflux management. PMC

6. Distinctive facial features, especially a broad nasal tip and thin, tented upper lip, which can become more obvious with age. PMC

7. Microcephaly (small head size) in a subset. PMC

8. Congenital heart defects, such as septal defects; not every child is affected but rates are higher than in the general population. PMC

9. Gastrointestinal issues, including constipation, poor motility, and vomiting. genetics.pediatrics.med.ufl.edu

10. Vision problems, e.g., strabismus (eye misalignment) or ptosis (droopy eyelid). BioMed Central

11. Behavioral features, including autistic traits or ADHD-like symptoms in some individuals. SFARI Gene

12. Seizures (less common than in some neurogenetic disorders, but reported). Kat6A

13. Sleep disturbance, such as frequent night waking. BioMed Central

14. Recurrent infections, especially early in life (reported in subsets). Kat6A

15. Growth issues in some children (poor weight gain early on), often linked to feeding difficulties. Unique

---

Diagnostic tests

A) Physical exam (what the clinician looks for)

1. General pediatric/genetics examination. A clinical geneticist looks for the pattern of features (developmental delay, facial traits, tone, growth) that suggest a chromatin-related neurodevelopmental disorder like KAT6A syndrome. BioMed Central

2. Dysmorphology assessment. Careful facial measurements and photographs (with consent) to document hallmark traits such as the broad nasal tip and thin, tented upper lip. This helps guide genetic testing. PMC

3. Cardiac exam. Detection of murmurs or signs of congenital heart disease prompts an echocardiogram. PMC

4. Neurologic exam. Assesses tone, reflexes, coordination, and signs of seizures or developmental motor issues. BioMed Central

5. Growth and nutrition assessment. Tracks weight/length/head size; poor growth may reflect feeding problems and reflux that need early support. PMC

B) “Manual” / bedside developmental and functional tests

6. Standardized developmental testing (e.g., Bayley, Mullen, WPPSI/WISC as age-appropriate) to profile cognitive, motor, and language levels and to plan therapies/education. BioMed Central

7. Adaptive behavior scales (e.g., Vineland) to understand daily-living skills and support needs. MDPI

8. Speech-language and oromotor evaluation, including tests for childhood apraxia of speech and feeding/oral-motor coordination; very relevant in KAT6A syndrome. MDPI+1

9. Behavioral/ASD assessment (e.g., ADOS-2/ADI-R when indicated) to identify autism traits and tailor interventions. SFARI Gene

10. Sleep screening tools (diaries/questionnaires); if concerns persist, consider polysomnography (see electrodiagnostics). BioMed Central

C) Laboratory / pathological and genetic tests

11. Chromosomal microarray (CMA). First-tier test for neurodevelopmental disorders to detect copy-number changes affecting KAT6A (rare) or other loci if the presentation is atypical. MDPI

12. Exome or genome sequencing. The key test that identifies single-nucleotide or small insertion/deletion variants in KAT6A (and other genes if differential is broad). Trio testing (child + parents) clarifies if a variant is de novo. PMC

13. Sanger confirmation and parental testing. Confirms the variant and determines inheritance (de novo vs familial), which informs recurrence risk. BioMed Central

14. RNA/splicing studies (when available). If the variant is near a splice site, RNA assays can prove mis-splicing. UQ eSpace

15. Targeted metabolic screening (rule-out). Basic labs may be used to exclude treatable metabolic causes when the diagnosis is still open; once a pathogenic KAT6A variant is confirmed, extensive metabolic testing is usually unnecessary. MDPI

D) Electrodiagnostic studies

16. EEG if seizures, staring spells, or regression are suspected. Abnormal EEG may support seizure diagnosis and guide anti-seizure therapy. Kat6A

17. Polysomnography (sleep study) if there is significant night waking, suspected sleep apnea, or hypoventilation, to guide sleep/ENT management. BioMed Central

E) Imaging and specialized organ evaluations

18. Brain MRI when indicated (e.g., seizures, abnormal neuro exam) to evaluate structural differences; some individuals with KAT6A have nonspecific findings. MDPI

19. Echocardiogram (heart ultrasound) at baseline, because congenital heart defects are more frequent in KAT6A syndrome than in the general population. PMC

20. Comprehensive ophthalmology assessment (with refraction and alignment testing) for strabismus/ptosis and visual needs; may include ocular imaging when appropriate. BioMed Central

Non-pharmacological treatments (therapies & others)

These approaches do not change the gene, but they often improve day-to-day skills, behavior, health, and family well-being. Always tailor to the child’s profile and local services.

1. Early Intervention & Individualized Education Plan (IEP). Starting therapies in infancy/toddlerhood and building a school-age IEP improves access to speech, occupational, and physical therapy, with goals broken into small, achievable steps; frequent review helps match supports to progress. Early, structured teaching is a cornerstone of better developmental outcomes in neurogenetic syndromes. PMC

2. Speech-Language Therapy with AAC. Intensive speech therapy focusing on receptive/expressive language plus augmentative and alternative communication (AAC) (e.g., picture exchange, speech-generating devices) can unlock communication even when verbal speech is very limited; AAC does not prevent speech and may accelerate it. PMC

3. Occupational Therapy (OT). OT targets fine-motor skills, hand-eye coordination, sensory processing, daily living tasks (dressing, feeding), and adaptive equipment. Sensory-smart strategies (e.g., weighted items, environmental cues) may reduce overload and improve participation at home and school. PMC

4. Physical Therapy (PT). PT addresses hypotonia, delayed gross motor milestones, balance, and endurance. Task-specific practice, bracing when indicated, and home exercise plans can improve mobility and reduce contracture risk in children with low tone. PMC

5. Feeding/Swallow Therapy & Nutrition Support. Feeding teams (speech/OT + dietitian) assess oral-motor skills, growth, reflux/constipation, and aspiration risk; plans may include texture modification, positioning, and supplemental calories. Severe or unsafe feeding may require nasogastric or gastrostomy tube to protect lungs and growth. PMC

6. Behavioral Therapy (e.g., ABA-informed strategies). Structured behavioral approaches help with routines, transitions, sleep hygiene, toileting, attention, and safety. Parent-mediated training generalizes gains to home life and reduces family stress. PMC

7. Social-Communication & Autism-support Programs. For children with autistic features, programs that blend social skills practice, visual schedules, and environmental accommodations can reduce distress and improve engagement, even without verbal speech. PMC

8. Vision Care & Strabismus Management. Regular ophthalmology checks address refractive errors and strabismus, which can impact learning and balance; early correction (lenses, patching, or surgery if needed) supports development. PMC

9. Cardiac Care Pathway. Because congenital heart defects can occur, cardiology evaluation (echo/ECG) with guideline-based management (medical/surgical) is important; early detection improves energy, growth, and exercise tolerance. PMC

10. Sleep Hygiene Program. Consistent schedules, light control, calming routines, and addressing nocturnal seizures or apnea can improve daytime behavior and learning; sleep studies may be needed if snoring or pauses occur. PMC

11. Hearing Evaluation & Supports. Audiology screening and hearing aids or classroom FM systems (when indicated) prevent “hidden” hearing loss from compounding speech/language delay. PMC

12. Gastrointestinal Care. Management of reflux, constipation, and feeding intolerance (dietary fiber, positioning, medical therapy as needed) reduces discomfort and supports participation in therapy and school. PMC

13. Orthopedic Monitoring. Hypotonia and delayed walking can affect alignment; orthotics, stretching, and serial monitoring help maintain function and prevent secondary complications. PMC

14. Psychology & Family Support. Counseling, peer groups, and respite support caregiver mental health, which directly influences child outcomes; social work can connect families with disability resources. PMC

15. Dental & Oral-Motor Care. Routine dental care, fluoride, and occupational/SLP oral-motor strategies reduce caries risk from feeding challenges and support safer swallowing. PMC

16. Immunization & Infection-prevention. Keeping routine vaccines up-to-date and promptly addressing recurrent infections is sensible; some reports suggest immune issues in a subset, warranting individualized assessment. ScienceDirect

17. Adaptive Technology. Tablets with symbol-based apps, switch access, or eye-gaze can enable learning and communication when motor or verbal skills are limited. PMC

18. Transition Planning (adolescence to adulthood). Plan for guardianship, vocational training, community living supports, and adult medical homes to preserve continuity and safety. PMC

19. Genetic Counseling. Families benefit from counseling on recurrence risk, options for future pregnancies, and cascade testing when a familial variant is present. search.thegencc.org

20. Clinical Trials/Research Registries (when available). Enrollment helps clarify the natural history and potential future therapies; families can stay updated on new findings about KAT6A biology and care. MDPI

---

Drug treatments

There are no FDA-approved drugs specifically for ADID-32. Medicines below are commonly used for associated symptoms (e.g., seizures, ADHD, sleep, behavior). Doses must be individualized by the child’s clinician; I list label-based ranges as context and cite the official FDA label for each. Off-label use should be discussed with your doctor.

1. Levetiracetam (Keppra) – Antiseizure. Purpose: reduce focal or generalized seizures that sometimes accompany neurodevelopmental syndromes. Mechanism: modulates synaptic vesicle protein SV2A to dampen hyperexcitability. Usual pediatric dosing is titrated; XR and solution forms exist. Watch for mood/behavior changes; rare psychosis or suicidality signal. Refer to label for indications and detailed titration. FDA Access Data+2FDA Access Data+2

2. Valproate/Divalproex (Depakote/ER) – Antiseizure/mood stabilization. Purpose: broad-spectrum seizure control when clinically appropriate. Mechanism: increases GABA; multiple channel effects. Typical pediatric dosing is weight-based with trough monitoring; boxed warnings include hepatotoxicity, pancreatitis, teratogenicity. Use with extreme caution in females of child-bearing potential. FDA Access Data+1

3. Lamotrigine (Lamictal/XR) – Antiseizure. Purpose: adjunct or monotherapy for focal/generalized seizures. Mechanism: voltage-gated sodium channel stabilizer, glutamate modulation. Requires slow titration to mitigate serious rash (Stevens–Johnson) risk; check interactions (e.g., valproate). FDA Access Data+2FDA Access Data+2

4. Topiramate (Topamax) – Antiseizure/migraine prevention. Purpose: adjunctive seizure control and sometimes for comorbid migraine. Mechanisms: sodium channel, GABA enhancement, carbonic anhydrase inhibition. Label warns about cognitive slowing, weight loss, kidney stones, metabolic acidosis; pediatric dosing is weight-based and titrated. FDA Access Data+2FDA Access Data+2

5. Methylphenidate (Ritalin / Ritalin LA) – Stimulant for ADHD symptoms. Purpose: improve attention, reduce hyperactivity/impulsivity when ADHD traits are present. Mechanism: blocks dopamine/norepinephrine reuptake. Labels include abuse/addiction boxed warning; titrate from low dose; monitor appetite, sleep, heart rate, and growth. FDA Access Data+1

6. Atomoxetine (Strattera) – Non-stimulant for ADHD. Purpose: alternative to stimulants when tics, anxiety, or side-effects limit use. Mechanism: selective norepinephrine reuptake inhibition. Boxed warning for suicidal ideation in youth; typical once-daily dosing is weight-based; monitor BP/HR and mood. FDA Access Data+1

7. Guanfacine ER (Intuniv) – Alpha-2A agonist for ADHD hyperactivity/impulsivity. Purpose: reduce hyperactivity, impulsivity, and help sleep onset. Mechanism: prefrontal noradrenergic modulation. Monitor for sedation, hypotension, bradycardia; taper to avoid rebound hypertension; once-daily dosing. FDA Access Data+1

8. Clonidine ER (Kapvay) – Alpha-2 agonist for ADHD/sleep initiation. Purpose: similar to guanfacine; sometimes helpful for sleep onset and hyperarousal. Mechanism: central alpha-2 agonism. Monitor for sedation and hypotension; don’t stop abruptly; bid dosing common per label. FDA Access Data+1

9. Risperidone (Risperdal) – Irritability/severe aggression associated with neurodevelopmental disorders. Purpose: treat severe irritability, aggression, self-injury when behavioral therapies are insufficient. Mechanism: dopamine/serotonin receptor modulation. Monitor weight, metabolic parameters, prolactin, and for movement side-effects; start low, go slow. FDA Access Data+1

10. Aripiprazole (Abilify / Abilify Maintena) – Irritability/aggression. Purpose: alternative atypical antipsychotic for severe behavioral dysregulation; partial dopamine agonist profile may lessen metabolic effects for some. Label includes warnings (e.g., akathisia); pediatric titration guidance available. Long-acting injection is for specific indications in older patients. FDA Access Data+2FDA Access Data+2

11. Baclofen (oral or intrathecal formulations) – Spasticity (if present). Purpose: reduce troublesome spasticity impacting comfort, mobility, or care. Mechanism: GABA-B agonist. Oral solutions/granules exist; intrathecal pump reserved for severe cases under specialist care; monitor for sedation and hypotonia. FDA Access Data+1

12. Tizanidine (Zanaflex) – Spasticity. Purpose: short-acting alternative for spasticity flares; may aid sleep via sedation. Mechanism: alpha-2 agonist at spinal level. Monitor LFTs, BP, and sedation; avoid abrupt withdrawal. FDA Access Data+1

13. Sertraline (Zoloft) – Anxiety/OCD/depression. Purpose: manage comorbid anxiety or OCD-like symptoms in older children/teens when psychotherapy alone is insufficient. Mechanism: SSRI. Boxed warning for suicidality in youth; start low, monitor activation/behavior. FDA Access Data+1

14. Fluoxetine (Prozac) – Anxiety/depression/OCD. Purpose: first-line SSRI in pediatric anxiety/OCD; long half-life may ease missed doses. Mechanism: SSRI. Boxed warning for suicidality; titrate slowly; watch for GI upset and activation. FDA Access Data+1

15. Topical/enteral reflux and constipation regimens (e.g., PPIs, osmotic laxatives) are often used for GI comfort; these are prescribed per standard pediatric guidelines, not specific to ADID-32; they support feeding and growth. Always follow label guidance for each product. PMC

16. Suvorexant (Belsomra) – Insomnia in appropriate older patients. Purpose: aid sleep initiation/maintenance when behavioral measures fail (age- and indication-appropriate). Mechanism: orexin receptor antagonism. Schedule IV; monitor for next-day somnolence and complex sleep behaviors. Not for young children. FDA Access Data

17. Rescue benzodiazepines (e.g., diazepam rectal gel) may be used per epilepsy plans for prolonged seizures; use strictly under neurology guidance because of respiratory depression risk. Label-specific details apply to each formulation. FDA Access Data

18. Migraine therapies (when comorbid, per neurology): topiramate (above) or other guideline-based agents; aim is to reduce pain-related school absence and sensory overload. Follow medicine-specific labels. FDA Access Data

19. Melatonin is a supplement (not an FDA-approved drug in the U.S.) sometimes used for sleep-onset delay; quality and dosing vary; discuss with your clinician. (See “Dietary supplements” below.) PMC

20. Combination care plans. Many families use small doses from different classes (e.g., stimulant + alpha-agonist) under close monitoring to balance benefits and side-effects, guided by label warnings and specialist input. FDA Access Data+1

---

Dietary molecular supplements

Supplements do not treat the genetic cause. They can support sleep, bone health, iron status, or general nutrition. Evidence quality varies; use products with reliable quality control and coordinate with your clinician, especially if your child takes antiseizure or psychotropic medicines.

1. Melatonin (sleep-onset). Description: Endogenous sleep hormone used short-term to cue bedtime; may improve sleep latency and reduce bedtime resistance. Typical pediatric starting doses are low (e.g., 1–3 mg 30–60 min before bed), titrated cautiously; timing matters more than dose. Mechanism: MT1/MT2 receptor agonism aligning circadian signals. Discuss interactions (e.g., with CNS depressants) and product quality. PMC

2. Omega-3 fatty acids (DHA/EPA). Description: May support general brain and retinal health and can modestly help attention or behavior in some neurodevelopmental cohorts; effects are usually small. Dosage varies by product (~250–500 mg DHA/EPA combined/day in children, per clinician). Mechanism: membrane fluidity, anti-inflammatory lipid mediators. Use certified-pure products. PMC

3. Vitamin D. Description: Supports bone health; many children with limited outdoor activity or restricted diets are low. Dose depends on baseline level and age; excessive dosing is harmful. Mechanism: calcium/phosphate homeostasis and neuromuscular function. Check labs before long-term supplementation. PMC

4. Iron (when deficient). Description: Iron deficiency can worsen fatigue, attention, and restless legs; treat only if lab-confirmed deficiency. Dose is weight-based elemental iron; use stool softeners if constipating. Mechanism: hemoglobin synthesis and neurotransmitter enzymes. Recheck ferritin/Hb to avoid overload. PMC

5. Calcium (diet + supplement as needed). Description: For children with dairy avoidance or low intake, supervised calcium may support bone accrual, especially if on meds that affect appetite. Dose depends on age and diet. Mechanism: skeletal mineralization. Avoid excess to prevent kidney stones (particularly with topiramate). FDA Access Data

6. Multivitamin (age-appropriate). Description: Fills minor micronutrient gaps in selective eaters; choose products with appropriate A, D, E, K, B-complex, and trace minerals without megadoses. Mechanism: general cofactor support. Avoid duplications with other supplements. PMC

7. Probiotics (for constipation/antibiotic-associated GI issues). Description: Certain strains may modestly improve stooling or reduce antibiotic-associated diarrhea; effects are strain-specific. Dosing by CFU per product; discontinue if bloating worsens. Mechanism: microbiome modulation. PMC

8. Fiber (in diet or supplement). Description: Soluble fiber can ease constipation and support gut comfort, improving feeding tolerance and sleep. Mechanism: stool bulking and fermentation to short-chain fatty acids. Ensure adequate fluids. PMC

9. Coenzyme Q10 (select migraine phenotypes). Description: Sometimes tried for pediatric migraine prevention with a favorable safety profile; evidence is mixed and low-quality; dosing varies (e.g., 1–3 mg/kg/day). Mechanism: mitochondrial electron transport. Discuss with neurology. FDA Access Data

10. Zinc (if low intake or deficiency). Description: Zinc deficiency impairs taste/appetite and immunity; supplement only if low by labs; excess zinc harms copper balance. Mechanism: enzyme cofactor. Coordinate testing and dosing with your clinician. ScienceDirect

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity-booster,” regenerative, or stem-cell drugs for ADID-32, and such products should not be used outside a regulated clinical trial for this condition. FDA-licensed hematopoietic stem-cell products (e.g., cord-blood–derived units) are approved only for hematologic reconstitution in specific diseases—not for neurodevelopmental disorders. If immune deficiency is suspected in an individual child, clinicians sometimes evaluate for standard indications for immune globulin therapy (IVIG/SCIG) using products like Gammagard/Hizentra/Cuvitru, but this is based on confirmed immunologic diagnoses, not for ADID-32 itself. Families should avoid unapproved stem-cell clinics. FDA Access Data

Because you asked for six drugs in this category with FDA sources: below are FDA-regulated products related to immunity or stem-cell contexts, listed only as examples of what the FDA actually approves for other indications—not as treatments for ADID-32. Use would be off-label and generally not recommended without a separate, clear indication.

• Immune Globulin (IVIG/SCIG)—e.g., Gammagard/Hizentra/Cuvitru. Human immunoglobulin for primary immunodeficiency; mechanisms include passive antibody replacement and immunomodulation. Dosing and route depend on product; adverse effects include headache, thrombosis risk in predisposed patients, and aseptic meningitis. Again, this is used when a patient meets immunology criteria, not for ADID-32 per se. FDA Access Data

• HPC, Cord Blood (various licensed products for hematopoietic reconstitution). Indicated for disorders like bone-marrow failure and certain hemoglobinopathies; not indicated for neurodevelopmental treatment. Risks include graft-versus-host disease, infection, and graft failure. Families should avoid unapproved “neuro” stem-cell offerings. FDA Access Data

(For safety and accuracy, I’m not naming additional “regenerative drugs” because the FDA does not approve them for ADID-32, and listing unrelated products could be misleading. Your best option is standard supportive care and registered trials.) MDPI

---

Surgeries

1. Congenital Heart Defect Repair. If echocardiography identifies defects (e.g., septal defects), cardiothoracic surgery may be recommended to improve growth, exercise tolerance, and reduce pulmonary complications; timing depends on defect type and symptoms. PMC

2. Strabismus Surgery. For persistent ocular misalignment that fails nonsurgical care, extraocular muscle surgery can improve binocular alignment, which helps function and reduces head turns. PMC

3. Gastrostomy Tube Placement. For severe dysphagia, poor growth, or recurrent aspiration, a G-tube provides safe nutrition/hydration and medication delivery, reducing hospitalizations and stress. PMC

4. Adenotonsillectomy for Obstructive Sleep Apnea. If polysomnography confirms significant OSA not responding to medical measures, removing enlarged tonsils/adenoids may improve sleep, daytime behavior, and growth. PMC

5. Orthopedic Procedures. If progressive deformities or contractures develop despite therapy and bracing, orthopedic procedures (e.g., tendon lengthening) can maintain mobility and hygiene. PMC

---

Prevention tips

1. Get the right early supports. Early therapies, IEPs, and AAC prevent secondary delays and frustration; waiting loses neuroplastic time. PMC

2. Routine screening. Schedule vision, hearing, dental, nutrition, and cardiac checks; catch problems before they derail progress. PMC

3. Vaccinations. Keep up-to-date to prevent infections that can trigger regressions or hospital stays. ScienceDirect

4. Sleep hygiene. Protect sleep to improve learning and behavior the next day. PMC

5. Seizure safety plan. Learn rescue steps and triggers if seizures occur; share the plan with school. FDA Access Data

6. Nutrition first. Address reflux/constipation and ensure adequate calories/protein; consider dietitian input early. PMC

7. Behavioral scaffolding. Use visuals and predictable routines to prevent meltdowns. PMC

8. Infection-prevention basics. Hand hygiene and prompt evaluation of recurrent infections, with immunology referral if indicated. ScienceDirect

9. Family mental health. Caregiver support prevents burnout and improves child outcomes. PMC

10. Genetic counseling for family planning. Understand inheritance, recurrence risk, and testing options. search.thegencc.org

---

When to see doctors

See your pediatrician and relevant specialists regularly (developmental-behavioral pediatrics, neurology, cardiology, ophthalmology, genetics). Seek urgent care for: new or prolonged seizures; breathing pauses at night; suspected aspiration (coughing/choking with feeds); poor weight gain or dehydration; severe constipation with pain; persistent lethargy, regression, or sudden behavior change; or chest pain/syncope. Ongoing care should track sleep, growth, behavior, learning, and therapy goals, with medication side-effect monitoring when used. PMC+1

---

What to eat & what to avoid

Eat more of:

1. Balanced meals with adequate protein (eggs, fish, legumes) to support growth and therapy stamina. PMC
2. Fruits/vegetables for fiber and micronutrients to ease constipation and support immune health. PM
3. Whole-grain fiber and fluids to maintain regular stools (important for comfort and sleep). PMC
4. Calcium/Vitamin D sources (dairy or fortified alternatives) to support bones, especially if appetite is reduced on stimulants. FDA Access Data
5. Omega-3–rich fish (when culturally acceptable) once or twice weekly for general health. PMC

Limit/avoid:

1. Highly processed sugary snacks/drinks that worsen dental risk and energy swings. PM
2. Excess caffeine (teens) that aggravates sleep and anxiety. PMC
3. Constipating low-fiber patterns (all refined carbs) when GI issues are present. PMC
4. Allergen-containing foods only if a true allergy/intolerance is diagnosed; otherwise avoid unnecessary restrictive diets. PMC
5. Unregulated “miracle” supplements or stem-cell products advertised for neurodevelopment—lack evidence and can be risky. MDPI

---

Frequently Asked Questions

1. Is ADID-32 the same as KAT6A syndrome? Yes—ADID-32/MRD32 refers to KAT6A-related disorder (Arboleda–Tham syndrome). PMC

2. How common is it? It’s very rare; most cases are single families worldwide, often with a de novo variant. PMC

3. Can my child outgrow it? The genetic change is lifelong, but skills grow with therapy, education, and medical care. PMC

4. Is there a cure or gene therapy? No approved disease-specific therapy yet; research is ongoing on chromatin disorders. MDPI

5. Will another child have it? If a parent carries the variant, each pregnancy has a 50% chance; if de novo, recurrence risk is low but not zero due to possible germline mosaicism—ask genetics. search.thegencc.org

6. Why is speech so affected? KAT6A influences brain development and gene expression; many children have severe speech apraxia/dyspraxia and benefit from AAC. PMC

7. Should we check the heart and eyes? Yes—baseline cardiology and ophthalmology evaluations are sensible because defects/strabismus are reported. PMC

8. Can seizures happen? They can; if there are staring spells, unusual movements, or regression, see neurology for EEG and plan. PMC

9. Are autism traits common? Many children show social-communication differences or ADHD-like features; supports should be individualized. Scholarly Publications

10. Which therapy is most important? Communication (SLP + AAC) usually has the biggest quality-of-life impact, but PT/OT, behavior, and school supports all matter. PMC

11. Do diets or supplements fix it? No; they can support health (e.g., iron for deficiency, vitamin D for bones) but don’t change the gene. PMC

12. Are there clinical trials? Rare-disease registries and occasional studies exist; your genetics team can help you find reputable opportunities. MDPI

13. What about stem-cell therapy ads online? Avoid—these are not FDA-approved for ADID-32 and may be unsafe. FDA Access Data

14. How can we help behavior? Combine structured routines, visual supports, caregiver training, and—if needed—careful medication trials with close monitoring. PMC

15. Where can I read more? Key overviews and cohort studies detailing features and management are available in open-access papers by Kennedy et al. and others. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.

PDF Documents For This Disease Condition References